Treatment of Executive Dysfunction in Parkinson's Disease
Status:
Completed
Trial end date:
2008-06-30
Target enrollment:
Participant gender:
Summary
Atomoxetine (Strattera) is a drug that is currently approved for treatment of attention
deficit hyperactivity disorder (ADHD) in children and adults. Atomoxetine works to enhance
levels of brain chemicals that may be affected in people with executive dysfunction,
(difficulties with organization, task completion, and priority setting). Thus, atomoxetine
has the potential to improve executive dysfunction in people with Parkinson's disease (PD).
The goal of this study is to provide preliminary data on the effectiveness and tolerability
of atomoxetine for the treatment of executive dysfunction in patients with PD.